Tresja Bolt

Tresja joined HLC in January 2022 with 22+ years of experience in Government Affairs & Policy, Market Access, Patient Advocacy and Policy & Issues Communications at International, EMEA, EU and Country levels. Most recently, Tresja was responsible for leading bluebird bio’s market- and access shaping strategies in support of the launch of its first gene therapies in Europe - defining, directing and executing fully integrated, cross-functional strategic stakeholder engagement plans in bluebird’s priority markets in Europe, Israel and GCC. She has an in-depth understanding and up-to-date knowledge and experience with healthcare and payer systems and patient access pathways across Europe. In addition, Tresja previously led the EMEA and Global Healthcare Practice of one of the leading independent Public Affairs firms worldwide and has extensive experience helping companies, trade associations, patient groups and international organisations build capacity and capability across the above areas of external affairs, including the development of training modules. Tresja is a regular speaker and lecturer at various institutions and conferences etc. She is fluent in Dutch and English with a good command of German.